Univariate Cox regression | Multiple Cox regression | |||||
HR | 95% CI | p Value | HR | 95% CI | p Value | |
Age at diagnosis | 1.01 | 0.99 to 1.02 | 0.052 | 1.01 | 1.006 to 1.03 | 0.002 |
Sex | 1.45 | 0.89 to 2.35 | 0.131 | 1.3 | 0.76 to 2.21 | 0.325 |
Renal impairment | 1.06 | 0.76 to 1.49 | 0.695 | 1.08 | 0.73 to 1.59 | 0.685 |
Neurological impairment | 1.57 | 1.005 to 2.46 | 0.047 | 1.78 | 1.05 to 3.02 | 0.03 |
Leucopaenia or lymphopaenia | 1.003 | 0.72 to 1.39 | 0.983 | 0.92 | 0.65 to 1.31 | 0.651 |
Thrombocytopaenia | 1.46 | 1.03 to 2.07 | 0.031 | 1.79 | 1.21 to 2.63 | 0.003 |
Haemolytic anaemia | 1.09 | 0.55 to 2.15 | 0.794 | 0.97 | 0.47 to 2.02 | 0.954 |
Persistent low complement | 1.29 | 0.86 to 1.92 | 0.204 | 1.29 | 0.83 to 2.01 | 0.257 |
Fluctuant complement | 0.83 | 0.56 to 1.24 | 0.384 | 0.67 | 0.42 to 1.05 | 0.081 |
Hydroxychloroquine | 0.67 | 0.41 to 1.109 | 0.121 | 0.37 | 0.21 to 0.66 | 0.001 |
Corticosteroid pulse | 1.17 | 0.83 to 1.66 | 0.358 | 1.05 | 0.64 to 1.70 | 0.843 |
Corticosteroid | 1.6 | 0.78 to 3.28 | 0.193 | 2.34 | 1.01 to 5.42 | 0.046 |
Immunosuppressive drugs (cyclophosphamide, mycophenolate and azathioprine) | 1.5 | 1.07 to 2.105 | 0.018 | 1.57 | 0.99 to 2.48 | 0.052 |
Biological therapy (rituximab and belimumab) | 1.38 | 0.74 to 2.57 | 0.301 | 1.14 | 0.59 to 2.18 | 0.693 |
Anti-dsDNA | 1.12 | 0.8 to 1.57 | 0.5 | 1.05 | 0.74 to 1.50 | 0.758 |
SLICC/ACR, Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index for Systemic Lupus Erythematosus.